LadRx Corporation · OTC:LADX

LadRx — Investor Presentation (November 2022)

20 slides from LadRx's investor presentation, November 2022

  1. Slide 1: Corporate Overview November 2022

    OTCQB:LADX CORPORATE OVERVIEW November 2022

  2. Slide 2: LadRx Corporation Safe Harbor Statement

    LadRx Corporation Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. SUCH STATEMENTS MAY BE PRECEDED BY THE WORDS “INTENDS,” “MAY,” “WILL,” “PLANS,” “EXPECTS,” “ANTICIPATES,” “PROJECTS,” “PREDICTS,” ESTIMATES,” “AIMS,” “BELIEVES,

  3. Slide 3: Management and Board

    Management and Board Board of Directors • Jennifer Simpson, PhD LadRx Chair of the Board. CEO of Panbela Therapeutics. Former CEO of Delcath, Oncology Stephen Snowdy, PhD Gilad Gordon, MD John Caloz Lead at Imclone, Product Director Oncology CEO R&D/Regulatory Consultant CFO Marketing at Ortho Biote

  4. Slide 4: Cancer is a massive burden

    Cancer is a massive burden In 2019, cancer claimed over 10 million lives worldwide1 Leading attributable causes (approx. half of cancers are attributable) are smoking, alcohol use, and high BMI 1 Cancer is the second leading cause of death in the US, behind heart disease2 Graphs Adapted from Center

  5. Slide 5: Investment Highlights

    Investment Highlights LadRx has developed elegant tumor targeting and release molecules called LADR that are based on LadRx is stage-diversified, with LADR-based drugs stretching small molecular entities (no complex antibodies or from registrational Phase 2 in pancreatic cancer to late pre- nanopart

  6. Slide 6: LADR=Linker-Activated Drug Release

    LADR=Linker-Activated Drug Release LADR-based drugs take advantage of circulating albumin as trojan horse: ➢ Major source of amino acids for tumors* ➢ Tumors use as carrier for metabolites, hormones, nutrients* ➢ Undergoes macropinocytosis* ➢ Accumulates in tumors due to EPR* ➢ Long half life* LADR:

  7. Slide 7: Near-term potential milestone/royalty payments and a pipeline of additional next-gen candidates

    Near-term potential milestone/royalty payments and a pipeline of additional next-gen candidates Doxorubicin reformulated with our LADR technology to improve therapeutic index. Licensed to Immunity Bio for up to $343M in potential milestones in addition to royalties on sales*. In Aldoxorubicin Regist

  8. Slide 8: Aldoxorubicin: 1st Gen LADR-Based Drug Has Proven Higher Dosing with Improved Safety

    Aldoxorubicin: 1st Gen LADR-Based Drug Has Proven Higher Dosing with Improved Safety in Human Trials Compared to Native Doxorubicin ➢ LADR allows for 3X higher dosing or more of doxorubicin When attached to LADR backbone, ➢ Aldoxorubicin crosses the Blood-Brain doxorubicin has Barrier been dosed in

  9. Slide 9: Aldoxorubicin: 1st Gen LADR Partnered with ImmunityBio

    Aldoxorubicin: 1st Gen LADR Partnered with ImmunityBio Trials have proven safety of higher dosing and efficacy Aldoxorubicin Preclinical Phase 1 Phase 2 Phase 3 Recurrent Glioblastoma P2A trial completed Immunity Bio moving into combo P2 Soft Tissue Sarcoma P3 showed safety/dosing, Immunity Bio cons

  10. Slide 10: ImmunityBio Metastatic Pancreatic Cancer Study QUILT-88

    ImmunityBio Metastatic Pancreatic Cancer Study QUILT-88 Pancreatic cancer will be diagnosed in 62k people in 2022 in the US, and will claim approximately 50K lives. Five-year survival is only 10%, and mean survival after 3 lines of therapy is 3 months 1 QUILT 88 study is a randomized, three cohort,

  11. Slide 11: Next-Gen LADRs: LADR 7, 8, 9, 10

    Next-Gen LADRs : LADR 7, 8, 9, 10 • High-throughput screening yielded four compounds selected for evaluation: • LADR 7: Auristatin-E with Ketone Linker • LADR 8: Auristatin-E with Ester Linker • LADR 9: Maytansine with Ketone Linker • LADR 10: Maytansine with Ester Linker • Auristatins and Maytansin

  12. Slide 12: LADRs 7 and 8 are powerful anti-cancer drugs in PDX/CDX models: Melanoma

    LADRs 7 and 8 are powerful anti-cancer drugs in multiple PDX/CDX cancer models: Melanoma

  13. Slide 13: LADRs 7 and 8 are powerful anti-cancer drugs in PDX/CDX models: Ovarian

    LADRs 7 and 8 are powerful anti-cancer drugs in multiple PDX/CDX cancer models: Ovarian

  14. Slide 14: LADRs 7 and 8 are powerful anti-cancer drugs in PDX/CDX models: Non-Small Cell Lung Cancer

    LADRs 7 and 8 are powerful anti-cancer drugs in multiple PDX/CDX cancer models: Non-Small Cell Lung Cancer

  15. Slide 15: ...As are LADRs 9 and 10

    .As are LADRs 9 and 10 w of the antitumor activity of maytansine and bumin-binding drugs in various human PDX and nograft tumor me glee rel els e. IEA bos 4 ABB 1 of b ils Flee z 3k & glelle/s lode ge glg/22 be eee 8 tle] eg mad a vPP EEE oem ARIE 25 & sls|s.3 cae [Ts 3 ame |e ora [ans | , ene ee oy

  16. Slide 16: All Four LADR Candidates Meet Initial Development Criteria

    All Four LADR Candidates Meet Initial Development Criteria Maytansinoid LADR™s (LADR- Auristatin LADR™s 9 and (LADR-7 and LADR-8) LADR-10) Selective Binding to Albumin and Stable in Plasma Payload Releases at pH 4 Robust Anti-Tumor Activity in Multiple Tumor Types Durable Responses Averaged 60‒90 Da

  17. Slide 17: Next-gen LADR Progress Towards IND

    Next-gen LADR Progress Towards IND ✓ Stability in plasma (mouse, rat, dog, monkey, human) ✓ pH-dependent release ✓ Rat and mouse MTD ✓ In-vitro efficacy ✓ In-vivo efficacy (small and large tumor PDX and CDX) ✓ Non-GLP rodent tox ✓ CMC GLP Mfg Run GLP rodent tox Non-GLP Non-Rodent MTD Time to IND 12-

  18. Slide 18: Potential milestones and royalties from KemPharm for Arimoclomol

    Potential milestones and royalties from KemPharm for Arimoclomol KemPharm KemPharm: Potential milestones Milestones and Royalties and royalties on arimoclomol Niemann-Pick disease (“NPC”) • Orphazyme filed an NDA with the FDA with Priority Review and received a Complete Response Letter on June 17, 2

  19. Slide 19: Upcoming Potential Catalysts

    Upcoming Potential Catalysts 2H22: Immunity Bio data on QUILT88 and meeting with FDA 2H22: Immunity Bio FDA meeting on Glioblastoma 3Q23: KemPharm submission to FDA for arimoclomol 2H22: Establish IND path for LADR 2H22-2H23: Updates on LADR advancement towards IND 1H24: First-in-human for LADR 7, 8

  20. Slide 20: Summary

    Summary LadRx has developed an efficient delivery platform for chemotherapeutic agents that takes advantage of the concentration of albumin in solid tumors. Being small molecules, the agents are easier/cheaper to manufacture than macromolecules, confer solubility, and crosses the blood-brain barrier

LadRx — Investor Presentation (November 2022) on 6ix